Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions

Prostate Cancer RecurrentRecurrent Prostate Cancer

Interventions

DIAGNOSTIC_TEST

[18F] PSMA-1007 Injection

a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.

Trial Locations (2)

London Health Sciences Centre, London

University Health Network - Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

collaborator

McDougall Scientific Ltd.

UNKNOWN

lead

Centre for Probe Development and Commercialization

OTHER

NCT04644822 - Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. | Biotech Hunter | Biotech Hunter